children and adverse effect in adults and the elderly. The risk estimates for ozone were robust to the adjustment of copollutants. After adjustment for ambient ozone, the 2 pollutants PM 2.5 and NO 2 are associated with higher risks of asthma hospitalizations in children. Sensitivity analyses with different metrics of ozone did not change the risk estimates significantly; the associations did not vary by sex or season; results with the young children group (< _6 years old) were similar to those with children younger than 18 years (see this article's Online Repository at www.jacionline.org). The current study disclosed age-dependent patterns of ozone and asthma relationships in an extended time window of lag0-20 days, which may help explain inconsistent findings of ozone and asthma in the earlier literature.
As a highly reactive gaseous pollutant, ozone exerts both inflammatory and antiviral effects in the respiratory system. The oxygen radicals produced from this exogenous oxidant evoke oxidative stress and airway inflammation, which would directly cause asthma exacerbation. Short-term exposure to ozone may also exacerbate asthma by increasing bronchial allergen responsiveness. On the other hand, ozone was shown to be protective against influenza by reducing influenza disease severity and mitigating acute virus-induced lung injury, 3 which may relate to the ozone-primed immunity via the alarmin IL-33 5, 6 against influenza virus infection. 7 The inflammatory and antivirus effects of ozone may exert opposite effects on asthma hospitalizations, explaining the differential effects of ozone on asthma in different subpopulations. Children are more vulnerable to respiratory infections because of their relatively weak immune system and more social gathering on school days. There are 80% to 85% asthma exacerbations in school-age children in the community associated with viral infection. 8 The inverse correlation between ozone and childhood asthma alludes to the antivirus effect of ozone and viral infections as a mediator for asthma hospitalization. The contribution of viral infection to asthma hospitalization may be larger in children than in adults and the elderly. In the children group, the protective effect of ozone was not observed in the immediate lag 0-2 days (Table I and Fig 1) , which may suggest that ozone's inflammatory effect was more immediate whereas its antivirus effects was more delayed.
There is a possibility that the real modifier of the ozone and asthma relationship is asthma phenotype instead of age itself because of the association between clinical phenotypes and age. 9 Furthermore, this study was conducted in Hong Kong, an Asian city with high density of population and higher pollution levels compared with Western countries. Replication of the current study is warranted in other geographical locations.
In conclusion, the reduced risk of asthma hospitalization in children stands in apparent contrast with the elevated risk in adults and the elderly associated with ambient ozone. Age or age-related asthma phenotype may be a modifier of the relationship between ozone and asthma. The differential effects of ozone on asthma reflect the complex roles of ozone in inducing both inflammatory and antiviral responses in different subpopulations. To the Editor: Primary immunodeficiencies (PIDs) encompass heterogeneous monogenic germline disorders, leading to defective development, function, or both of the immune system. The highly varied clinical manifestations along with often narrow initially recognized phenotypes can hamper accurate diagnosis in patients with rare and novel PIDs. At present, whole-exome sequencing (WES) enables the discovery of atypical traits of monogenic syndromes, broadening their phenotypic spectrum. Among reported PIDs, deficiency of adenosine deaminase 2 (DADA2) was originally associated with systemic autoinflammation, polyarteritis nodosa (PAN)-type vasculitis, and mild immunodeficiency. 1, 2 Further studies have expanded the clinical phenotypic spectrum of DADA2 to cover common variable immunodeficiency, Blackfan-Diamond anemia, immune dysregulation, and spastic paraplegia. [3] [4] [5] [6] [7] Clinical exome sequencing of 291 unrelated Finnish patients with PIDs identified 4 patients with biallelic loss-of-function variants in CECR1, the gene encoding adenosine deaminase 2 (ADA2; Table I ). The detailed phenotypes of all patients with DADA2 (see Fig E1 and Tables E1 and E2 in this article's Online Repository at www.jacionline.org), and the processing and analysis of the WES data are described in the Methods section in this article's Online Repository at www.jacionline.org. All patients are from nonconsanguineous families and share the p.Arg169Gln mutation, 3 as homozygous (P1-P3) and 1 (P4.1) as a compound heterozygous with the novel pathogenic p.(Leu311Arg) variant (see Table E3 and the Methods section in this article's Online Repository at www.jacionline.org). Analysis of the WES data revealed no other compelling variants in the previously described PID-causing genes or pathogenic or likely pathogenic variants in other genes that could contribute to the phenotypes based on current knowledge (see Table E4 in this article's Online Repository at www.jacionline.org).
The identified patients showed considerable phenotypic heterogeneity, all presenting with variable cytopenias, without vascular or hemorrhagic complications. Interestingly, 3 patients (P1-P3) were displaying lymphoproliferation, and 2 of them exhibited a CD3
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CD8
1 T-cell large granular lymphocytic (T-LGL) infiltration of the bone marrow (P1 and P2). In P1 autoimmune findings suggestive of T-LGL were reported first at the age of 8 years and proved at age 17 years. P2 was given a diagnosis of T-LGL at age 31 years. Because the phenotype of P1 and P2 clinically resembled that seen in patients with GATA2 deficiency or those with activating signal transducer and activator of transcription 3 (STAT3) mutations (autoimmunity, hypogammaglobulinemia, and lymphoproliferation), we further ruled out germline defects in these genes, as well as the haploinsufficiency of GATA2 (see the Results section in this article's Online Repository at www.jacionline.org). The clinical evaluation of P3 at the age of 4 years showed lymphadenopathy and T-cell hyperplasia in the bone marrow. P4 was 5 years old at the time of the evaluation; thus considering the variable onset of lymphoproliferation seen in the other patients, we cannot exclude the possibility that she could have lymphoproliferation later in life. These findings represent the first link between DADA2 and early-onset T-cell clonal expansion. The targeted screening of the patients' relatives identified 2 additional CECR1 p.Arg169Gln homozygotes: an asymptomatic sister of P2 (F2-3) and a symptomatic aunt of P4.1 (P4.2).
F2.3 presented with mild cytopenias, and detailed immunologic evaluation at the age of 46 years revealed her to also carry a marginal T-LGL clone in peripheral blood (0.06 3 10 26 /L), although not fulfilling the criteria of T-LGL leukemia. P4.2 was initially given a diagnosis of combined variable immunodeficiency, and further examination at the age of 18 years revealed signs of lymphoproliferation.
Our exome sequencing study also identified a multicase family originating from eastern Finland and given a diagnosis of cutaneous PAN and central nervous system complications (Fig 1) . Interestingly, a follow-up of more than 40 years showed that the patients experienced all the DADA2 vascular flares after carefully documented bacterial respiratory tract or dental infections, with or without adequate treatment with antibiotics. In P6 and P7 the possibility of lymphoproliferation was ruled out in their late 1930s. P5 to P7 carried compound heterozygous variants in CECR1: p.Arg169Gln and the novel donor-splice variant c.973-2A>G (Table I and see Table E3 ). The analysis of the CECR1 transcripts in the 2 living patients (P6 and P7) showed the occurrence of nonsense-mediated decay triggered by a premature stop codon induced by the splice variant. The resulting monoallelic expression of p.Arg169Gln resembles that seen in the 4 patients with lymphoproliferative phenotypes (P1-P3 and P4.2 homozygotes for p.Arg169Gln). This suggests that either the lack of 1 CECR1 allele or other genetic and/or environmental factors can modify the phenotype.
T-LGL leukemia is a rare lymphoproliferative disease manifesting typically with clonal expansion of CD3
CD57
1 cytotoxic T lymphocytes and often in association with systemic autoimmunity, cytopenias, and occasionally with primary pulmonary hypertension. Therefore we screened for T-cell clonality in the 2 patients with LGL lymphoproliferation using a flow cytometry-based assay. The results showed clonal Vb expansions in the CD8 1 fraction in P1 (Vb.5.1, 18.8%; Vb.1, 12.4%; data not available for P2). Previously, we have shown that aberrant STAT3 signaling caused by somatic mutations in the dimerization Src homologue 2 (SH2) domain of STAT3 can cause constitutive Janus kinase-STAT pathway activation underlying T-LGL pathogenesis. 8 Hence we investigated the STAT3 SH2 domain in PBMCs of P1 to P4 and P6 to P7 by using deep targeted sequencing. Four STAT3 mutations were identified in the patients displaying the T-LGL phenotype (P1 and P2) and none in the others (see the Results section in this article's Online Repository). All the clonal variants have been reported to cause constant STAT3 activation in patients with T-LGL leukemia. 8, 9 However, in contrast to patients with classical T-LGL, the somatic STAT3 gain-of-function variants retrieved were not confined to 1 clonal cell subpopulation or observed in all the clonally expanded CD8
1 cells in patients with DADA2. Therefore it is unlikely that the depicted variants could account for the lymphoproliferative phenotype observed in the patients.
In this study we identified the p.Arg169Gln mutation, which was previously proved to cause DADA2, 1,2 in 8 patients with highly varied clinical manifestations. The variant exhibits a significant enrichment in Finns compared with other European populations (3.31-fold, P < 1e 28 , see Table E3 and the Results section in this article's Online Repository). As shown for other PID-causing mutations, 9 the genetic background of Finns reflects the limited number of founder alleles, isolation, several population bottlenecks, and recent expansion, which have enabled enrichment of some deleterious variants, the homozygosity of which typically causes most of the observed cases.
In conclusion, we have expanded the phenotypic and mutation spectrum of DADA2. We complemented the characterization of both the classical vasculitic phenotype and atypical traits, describing, for the first time, a lymphoproliferative phenotype in a subset of patients with the homozygous c.G506A mutation in CECR1. In 2 patients the lymphoproliferation resembled T-LGL. It is possible that other genetic and/or environmental factors contribute to the T-LGL phenotype. Nonetheless, our findings indicate how challenging a presumptive diagnosis in patients with DADA2 can be because of the wide clinical spectrum. DADA2 should be considered in cases of early-onset lymphoproliferation to ensure early detection, thorough follow-up, and active treatment. 
METHODS
Study subjects
The study was undertaken in compliance with the principles of the Helsinki Declaration and approved by the ethics committees of Helsinki and Oulu University Central Hospitals, Finland. All patients provided written informed consent before sample collection. Clinical evaluations of patients was carried out at the Helsinki and Oulu University Hospitals and complemented with archived medical records of P5 to P7 from Kuopio University Hospital.
The clinical cases presented were part of a cohort of 291 unrelated Finnish patients with PIDs undergoing clinical exome sequencing. The cohort was not selected for DADA2 or another specific disease and comprised a broad spectrum of potentially monogenic immune disorders. The patients were included based on clinical diagnosis, laboratory findings, or both suggestive of immune phenotypes. Clinical signs of lymphoproliferation monitored in the patients were as follows: T-LGL leukemia, excess lymphoid cells in peripheral blood or bone marrow, lymphadenopathy, and (hepato-)splenomegaly. Detailed phenotypes of all the patients are presented in Table I, Tables E1  and E2 and Fig E1. In early childhood P1 (44 years old, female) presented with Evans syndrome, hepatosplenomegaly, skin warts, and later severe human papilloma virus-associated vulvar cellular atypia. She had further autoimmune findings, suggesting T-LGL lymphoproliferation since age 8 to 10 years that was proved only at age 17 years. She later experienced disseminated histoplasmosis, pulmonary arterial hypertension, and severe panhypogammaglobulinemia. She had low total B, switched memory B, and naive CD3 1
CD4
1 T-cell counts. At age 26 years, P2 (41 years old, female) was given a diagnosis of Coombs0negative hemolytic anemia and splenomegaly. At age 31 years T-LGL lymphoproliferation of the bone marrow was diagnosed together with neutropenia, hepatomegaly, iritis, and systemic lupus erythematosus-like skin lesions. At age 38 years, she experienced autoimmune hepatitis and hepatopulmonary syndrome.
LGL infiltration was found also in the liver. Since the age of 38 years, she has needed regular red blood cell transfusions. Also, her numbers of switched memory B, NK, and dendritic cells were low. Proportions of activated CD21 low B cells, DR1CD4 cells, and CD8 effector memory RA T cells were increased.
F2-3 (46 years old, female) is the sister of P2 and was identified as a p.Arg169Gln homozygote after screening for the familial CECR1 mutation (Fig 1) . She is apparently healthy, but thorough immunologic evaluation showed low IgM levels and NK cell numbers and low response to diphtheria vaccination. Analysis of T-cell clonality detected a small T-LGL clone in peripheral blood (0.06 3 10 26 /L). The size of the clone was considered too limited to fulfill the criteria for a diagnosis of T-LGL leukemia. As a newborn, P3 (6 years old, female) was given a diagnosis of Diamond-Blackfan-type anemia and thrombocytopenia. At the time of evaluation, she experienced recurrent fevers, a large spleen, lymphadenopathy (reactive follicular hyperplasia), grade I myelofibrosis (granulocyte, erythroid, and T-cell hyperplasia in bone marrow), and neutropenia; low numbers of NK cells and high levels of IL-2 receptor were detected. Allogeneic stem cell transplantation was performed in September 2016. Comparative genomic hybridization investigating developmental delay, dysmorphic features, and idiopathic epilepsy revealed 15q26.1-q26.2 deletion.
P4.1 (7 years old, female) presented from 3 months of age with mild signs of anemia, leukopenia and thrombocytopenia, and severe neutropenia. At age 5 years she experienced severe splenomegaly, and the dermatologist diagnosed vasculitis and purpura lesions. At 6 years of age, she presented with skin warts. At age 7 years, she received a diagnosis of carpal synovitis in carpometacarpal joints.
P4.2 (18 years old, female) was included in the study after screening for the familial CECR1 mutations, which showed her as a p.Arg169Gln homozygote.
At age 13 years, she was given a diagnosis of combined variable immunodeficiency and treated accordingly. She presented with Raynaud syndrome, thrombocytopenia, and low (almost nonexistent) response to vaccination. Thorough immunologic evaluation showed low IgA, IgG, and IgM levels; high numbers of CD19 1 B cells; and low activation of the mannan-binding lectin complement pathway. Abdominal ultrasonography performed in May 2017 revealed mild splenomegaly (diameter, 12.9 cm) and para-aortal lymphadenopathy. A multicase (n 5 3) DADA2 family originating from eastern Finland has been clinically followed up for more than 40 years (Fig 1) . P5 had chronic lymphopenia from infancy, unusually recurrent bacterial respiratory and periodontal infections, chronic livedo reticularis racemosa, episodes of seizures, and slowly progressive but severe neurologic impairment and cognitive decline. These were accompanied by documented central nervous system polyarteritis nodosa. He eventually died at age 16.5 years.
His 2 sisters (P6 and P7) shared an identical phenotype but had milder and less progressive, inoperable vascular central nervous system lesions (aneurysms and vasculitic narrowing) and acute intracerebral hemorrhages. In all siblings numerous documented bacterial respiratory tract and periodontal infections were complicated by vasculitic flares, fevers, and seizures 2 to 4 weeks later. In the surviving siblings we showed monoallelic expression of p.Arg169Gln caused by nonsense-mediated decay of the other allele induced by the novel donor-site splicing variant c.973-2A>G.
DADA2 measurement
Levels of ADA2 activity in plasma were measured in 7 subjects, as previously published, showing them as deficient in plasma ADA2 activity (Table I ). The samples were analyzed in 2 different laboratories, as previously shown. E1 For patients P1, P2, P6, and P7, the level of DADA2 activity was measured on EDTA-treated plasma (expressed as milliunits per milliliter) with the following reference values: 12.8 mU/mL (SD, 2.6 [minimum-maximum]) in adults (>18 years old) and 27 mU/mL (SD, 2.3 [minimum-maximum]) in children (<18 years). In a second stage the remaining patients (F2.3, P4.1, and P4.2) were analyzed on filter paper (activity measured in milliunits per gram of protein) with reference values for plasma ADA2 activity: 4.7 6 4.8 for ADA2-deficient subjects (n 5 44), 54.9 6 24.0 for ADA2 carriers (n 5 31), and 264.0 6 200.6 for subjects at risk but not deficient (n 5 136). The previously mentioned method was modified partly to be executed on filter paper.
E2 Patient P3 was not tested since she underwent allogeneic stem cell transplantation in September 2016; P5 died in 1990.
Molecular genetics
DNA and RNA for genetic analyses were extracted from PBMCs by using standard methods. WES was performed in 4 patients with sporadic DADA2 (P1-P4.1) using a SureSelect Clinical Research Capture Exome kit (Agilent, Santa Clara, Calif). The sequencing was performed by using HiSeq 1500 Rapid Run (Illumina, San Diego, Calif), as previously described. E3 WES on 4 members of a multicase family (patients P6 and P7 and the 2 unaffected relatives, F5-1 and F5-2) was executed by using a Nextera Rapid Capture Exome kit (Illumina). WES data were analyzed by using version 2.7 of the in-house developed analysis pipeline for quality control and variant identification (VCP). E4 Raw Illumina reads were first merged with SeqPrep (0.4.5). The resulting paired reads were trimmed of number blocks in quality scores from the end of the read. After this, any read shorter than 36 bp was removed. The paired and single reads were aligned separately by using the Burrows Wheeler Aligner (version 0.5.10) against the human genome (Ensembl version 70). Alignment was refined by using GATK Indel Realignment (version 1.5-3). After alignment, potential PCR duplicates were removed with Picard mark duplicates (version 1.65). Also, any read pair in which both reads or any single read were mapping to multiple genomic positions were removed. Variant calling was performed with SAMtools mpileup (version 0.1.18) and dindel (version 1.01). The single nucleotide polymorphisms (SNPs) were called with a minimum depth of 7. The resulting SNPs were then recalculated by using quality values. A ratio between the sum of quality values of reference (R) and variant (V) calls was calculated as follows:
R=ðR1VÞ;
discarding any values for which the ratio was greater than 0.8. If there were 2 variant calls and no reference, the call with higher-quality values was used in place of reference. Any call with a ratio of less than 0.2 was assumed to be homozygous, and the rest were assumed to be heterozygous. Annovar was used for annotations and prediction of functional consequences of the identified variants.
E5,E6 All common (frequencies >0.01 in the general population) and noncoding variants were discarded. Frequency filtering was based on data from the Genome Aggregation Database (gnomAD, Cambridge, Mass; http://gnomad.broadinstitute.org/; accessed May 2017) and the national SISu project (http://sisu.fimm.fi/). E7,E8 In addition, we discarded all variants exceeding a frequency of 0.05 according to an internal-use database. Rare variants affecting the coding regions were filtered based on predicted consequences at the transcript level, with selection of frameshift, nonsense, splicing, and missense variants. All filtered variants were evaluated further according to the American College of Medical Genetics and Genomics Standards and Guidelines E9 and prioritized by using the predicted effect on the protein, the conservation of the affected amino acids, and in silico prediction tools (Tables E4). Data were analyzed with an in-house bioinformatics pipeline. For the multicase family, the known segregation pattern of the disease in the family was taken into account in filtering of the variants. P6 and P7 shared a total of 184,364 variants (173,294 SNPs and 11,070 indels), of which 2,557 were rare and located in the coding region. We searched for shared genotypes according to the inferred autosomal recessive inheritance pattern and pinpointed a list of candidate genes based on the presence of homozygous (n 5 10) or compound heterozygous (n 5 8) variants. Among the candidates, only 1 of the compound heterozygous variants we observed in the CECR1 gene was likely to cause the observed phenotype.
All the CECR1 (Ensembl ENSG00000093072, ENST00000399837; GRCh37.p13) variants identified by using WES in P1, P2, F2-3, P6, and P7 were shown as pathogenic (Table E3 ) and confirmed by using PCR amplifications of genomic DNA and capillary electrophoresis on the ABI-3730XL DNA Analyzer and BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, Calif). The same method was used for screening of familial mutations in all available family members. Sequencing data were analyzed by using Sequencher (Gene Codes, Ann Arbor, Mich). Variants were further confirmed at the transcript level by means of capillary sequencing conducted on cDNA. cDNA was obtained from PBMC RNA by using the SuperScript VILO cDNA Synthesis kit (Life Technologies, Carlsbad, Calif), according to the manufacturer's instructions (by using 0.5-2 mg of RNA in a 20-mL reaction volume). Sequences of all the forward and reverse primers used for PCR amplifications and capillary electrophoresis are available on request.
The possibility of GATA2 haploinsufficiency was ruled out in P2 through Sanger sequencing of cDNA (obtained from PBMC RNA, as described above), showing the presence of both alleles based on confirmation of a heterozygous SNP in the coding region of the gene previously detected by using WES. Because of the absence of heterozygous variants in the coding region of GATA2 in P1, we excluded the presence of all coding and intronic variants reported in the Human Gene Mutation Database (https://portal. biobase-international.com/hgmd/) as causing haploinsufficiency. Screening of somatic variants in the functional SH2 domain of STAT3 (Ensembl ENSG00000168610, ENST00000588969; GRCh37.p13) was performed in patients P1 to P4 and P6 to P7 and in 2 technical control subjects (healthy) to monitor for potential variants. Screening was executed by means of deep amplicon sequencing of exons 19, 20, and 21 of STAT3 on the Illumina Miseq platform (Illumina), as described previously. E10 Variants surviving the filtering criteria shared or carried by P1 and P2 in the same genes are presented in Table E4 .
T-cell clonality analysis
T-cell clonality was screened in the 2 patients with LGL lymphoproliferation (P1 and P2). Clonal expansions in peripheral blood samples were assessed with the IO Test Beta Mark TCR Vb Repertoire Kit (PN IM3497; Beckman Coulter, Immunotech, Marseille, France), which is a kit for quantitative determination of the T-cell receptor (TCR) Vb repertoire of human T lymphocytes by using flow cytometry. The kit consists of 8 vials containing mixtures of conjugated TCR Vb antibodies corresponding to 24 different specificities covering approximately 70% of the normal human TCR Vb repertoire. Normal means with minimum and maximum values were provided by the manufacturer and have been derived from a cohort of 85 normal blood specimens (except for the tube detecting Vb4, Vb7.2, and Vb13.2 use, which was tested on a different cohort of 46 normal specimens). Samples were also stained with CD3, CD4, and CD8 antibodies (BD Biosciences, Franklin Lakes, NJ) to further characterize the expansions.
T-cell sorting
From patients P1 and P2, PBMCs were further sorted into CD8 1 and either CD8 2 or CD4 1 populations by using flow cytometry (Multitest CD45, CD3, CD8, and CD4 antibodies; BD Biosciences). A small amount of cells from the sorted fractions was used to check sorting purity (FACSAria; Beckman Coulter, Immunotech).
Statistical analysis
The Pearson x 2 test (10 8 simulations) was used to evaluate the allelic distribution of CECR1 variants among different populations (data from gnomAD).
RESULTS
Screening of familial samples for CECR1 mutations
We identified F2-3 and P4.2 (sister of P4.1) to be homozygous for p.Arg169Gln and a historical DNA sample from P5, the deceased brother of P6 and P7, as a compound heterozygote (c.G506A; p.Arg169Gln/c.973-2A>G).
T-cell clonality analysis
Screening of T-cell clonality showed clonal Vb expansions in the CD8
1 fraction (Vb.5.1, 18.8%; Vb.1, 12.4%) in P1 (data not available for P2).
Screening of mutations in the SH2 domain of STAT3
Screening conducted by using deep targeted sequencing on DNA from PBMCs identified 4 STAT3 mutations in patients displaying the T-LGL phenotype and none in the others. The mutations were further monitored in the sorted CD8
1 T-cell fraction and in the CD8 
